Litcius/Paper detail

Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

BioNTech Se

2021ClinicalTrials.gov16 citations

Abstract

Condition: Covid-19;COVID-19 Related Psychosocial Burden Primary outcome: Structural and process quality of COVID-19 related psychosocial consultation and liaison (CL) services s Criteria: Inclusion Criteria: - heads of all psychosomatic, psychiatric and psychological consultation and liaison (C&L) services in acute care hospitals (across all participating countries) Exclusion Criteria: - None.

Topics & Concepts

PsychosocialMedicineCoronavirus disease 2019 (COVID-19)Inclusion and exclusion criteriaImmunogenicityTolerabilitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakFamily medicinePsychiatryAlternative medicineVirologyAdverse effectImmunologyInternal medicineDiseaseInfectious disease (medical specialty)Immune systemPathologyOutbreakCOVID-19 Impact on ReproductionVaccine Coverage and HesitancyCOVID-19 and Mental Health
Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older | Litcius